![]() | ![]() |
Formats:
|
||||||||||||||||||
Persistent Transcription of a Non-integrating Mutant of Simian Immunodeficiency Virus in Rhesus Macrophages Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, Maryland, USA 20892 *Corresponding author. 4 Center Drive, Rm B1-41, Bethesda, Maryland 20892, Tel: (301) 496-0559, Fax: (301) 480-3129. E-mail address: vhirsch/at/niaid.nih.gov The publisher's final edited version of this article is available at Virology.Abstract A non-integrating mutant, SIVsmD116N, was derived from the infectious pathogenic SIVsmE543-3 clone by introducing an Asp (D) to Asn (N) mutation into the catalytic domain of integrase. Although SIVsmD116N generated all viral proteins following transfection, cell free virus did not productively infect CEM×174 cells, macaque peripheral blood mononuclear cells (PBMCs) or monocyte-derived macrophages (MDM). Viral DNA and transcripts were observed transiently in SIVsmD116N-infected CEM×174 cells and macaque PBMC but persisted in MDM for as long as 20 days. Circular forms of viral DNA were detected but there was no evidence of integration detected by Alu PCR. We found that SIV D116N mutant remained transcriptionally active and expressed low levels of viral proteins persistently in MDM. These data are consistent with a role for macrophages as a persistent latent reservoir for AIDS viruses. The capacity of non-integrating SIV to persistently generate viral products in macrophages suggests that non-integrating lentiviral vectors could be engineered to efficiently and safely express proteins for vaccine purposes. Keywords: Simian immunodeficiency virus, Non-integrating mutant, Transcription, Macrophage Introduction As retroviruses, human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) must accomplish sequential events to achieve successful infection. Following viral entry and reverse transcription, the newly synthesized viral DNA integrates into the host chromatin (Bukrinsky et al., 1992). Integration is mandatory for viral production, but HIV/SIV infection in vivo results in high levels of non-integrated DNA (Wu, 2004). Prior work has demonstrated transient expression of both early and late message by non-integrated HIV DNA in CD4 T cells (Stevenson et al., 1990; Wiskerchen and Muesing, 1995). The transcription from non-integrated DNA is a normal and early step in HIV replication. Non-integrated DNA has the capacity to synthesize all classes of viral transcripts, early, multiply-spliced, late, singly-spliced, and non-spliced transcripts, prior to integration (Wu and Marsh, 2003a). The capacity of pre-integration HIV DNA to transcribe is of interest, since about half of the reverse transcribed DNA from HIV infection does not integrate into the cellular DNA. Previous report shows that about 45% of HIV DNA is not integrated (Zennou et al., 2000), but the biological relevance and possible pathogenic role of non-integrated viral DNA is not clear (Wu and Marsh, 2003b). The non-integrated viral DNA has been shown to carry transcriptional activity in human CD4 T cells and it can direct limited syntheses of viral early proteins such as Nef. It has been demonstrated that Nef synthesized from non-integrated DNA can promote T cell activity and down regulate CD4 molecules (Gillim-Ross, Cara, and Klotman, 2005b). These observations prompted us to evaluate SIV viral gene expression in non-dividing macaque macrophages infected with a non-integrated mutant SIV virus. In this study, we constructed a non-integrated mutant, SIVsmD116N (D116N), and evaluated its ability to replicate, transcribe and express viral proteins following infection of macrophages in vitro. Results Non-integrating SIV mutant and reverse transcriptase assay for its infectivity In previous research, HIV-1IN/D116N mutant was derived by introducing an Asp (D) to Asn (N) mutation within the integrase D(35)E motif. This single point mutation has been shown to completely abolish viral DNA integration of HIV without affecting other known viral functions such as reverse transcription and nuclear targeting (Engelman et al., 1995). In this study, we constructed a non-integrating mutant of SIV, using the infectious molecular clone, SIVsmE543-3 as a parent. SIVsmE543-3, derived from a biological isolate obtained late in disease from an immunodeficient rhesus macaque (E543) with SIV-induced encephalitis (Hirsch et al., 1997) replicated efficiently in macaque peripheral blood mononuclear cells (PBMCs) and monocyte-derived macrophages (MDM) in vitro and induced AIDS when inoculated intravenously into macaques (Dehghani et al., 2003; Hirsch et al., 1997; Hirsch et al., 2004). The non-integrating mutant, SIVsmD116N, was derived from SIVsmE543-3 by a “G” to “A” substitution at site 4877, resulting in an Asp (D) to Asn (N) substitution into the integrase catalytic domain. The wild type (WT) and mutant plasmids were transfected to 293T cells and produced comparable levels of cell free reverse transcriptase activity (data not shown). Western blot analysis of cell free virus supernatants revealed a similar pattern of viral proteins (Fig. 1
Persistence of non-integrated viral DNA in macrophages Since previous studies of HIVD116N demonstrated persistence and expression in resting T cells, we chose to focus on macrophages, another non-dividing target of HIV/SIV. PCR was used to investigate whether SIVsmD116N was capable of entering and replicating in monocyte derived macrophages (MDM) in vitro. Total cellular DNA from WT and SIVsmD116N infected macrophages was isolated at different times post infection and PCR amplified with primers specific for SIV late DNA, 1-LTR-circles and 2-LTR-circles DNA. Production of SIV full length DNA was indicated by the detection of a LTR product using SIV/DNA-5 and SIV/DNA-3 primers (see Table 1). Circular viral DNA forms were also detected using SIV/Circle-5′ primer and SIV/Circle-3′ primer. Based on detection of full length viral DNA, the SIVsmD116N mutant was able to synthesize viral DNA in MDM with equal efficiency to the WT virus. Viral DNA synthesized from SIVsmD116N persisted for 20 days (the termination of culture) at a level comparable with the WT virus (Fig. 3A
SIVsmD116N did not integrate into genomic DNA in either T cells or macrophages To determine whether SIVsmD116N was capable of integration into the host genome, we used an Alu sequence-based PCR strategy (Zhuge et al., 2001). The Alu sequence is a ubiquitous repeat element found in the human/monkey genome but absent in the HIV/SIV genomes which can be used to specifically demonstrate whether viral DNA is integrated into the host chromosome. As expected, DNA was amplified from as few as 103 CEM×174 cells infected with SIVsmE543-3, consistent with the presence of proviral DNA in these cells (185 bp product). In contrast, no product was detected in up to 2.5×104 CEM×174 T cells infected with SIVsmD116N virus (Fig. 4A
Persistence of transcriptional activity from non-integrated viral DNA in macrophages To determine transcriptional activity of non-integrated viral DNA in macrophages, total cellular RNA was isolated and amplified by semi-quantitative RT-PCR at different times post infection (Wu and Marsh, 2001). Briefly, reverse transcription of cellular RNA was accomplished with random decamers as the first-strand primers. Following cDNA synthesis, PCR was carried out using primers to detect the specific messages of SIV using the primers detailed in Table 1. Primer combinations used the same forward primer, SIV/5′ and four different reverse primers, SIV/nef-tat-rev, SIV/3′env, SIV/3′vif and SIV/3′gag-pol to detect multiply, singly and unspliced messages. For relative quantification of RT-PCR, cellular β-actin transcripts (294 bp) were co-amplified using QuantumRNA β-actin Internal Standards (Ambion, Austin, TX), with a ratio of 3/7 for actin primer/competitor. The PCR results were compared between WT and SIVsmD116N based upon the reference of co-amplified cellular β-actin transcripts. Consistent with the persistence of non-integrated DNA, the viral transcription in SIVsmD116N infected macrophages was also persistent. In contrast to the transient presence of viral DNA and its transcripts in T cells (Wu and Marsh, 2003b), the non-integrated viral DNA in macrophages remained transcriptionally active until the termination of the cultures at 20 days. However, RNA expression levels of the SIVsmD116N mutant were much lower than that of WT virus. As shown in Figure 5A
Protein synthesis from SIVsmE543 and SIVsmD116N viruses in macrophages The capacity of non-integrated viral DNA to direct viral protein synthesis in infected macrophages was examined by western blot analysis of cell lysates. Macrophages were cultured and divided into 3 groups: infected with SIVsmE543 or SIVsmD116N, and uninfected. Cells were harvested at different times and total cellular proteins were extracted and resolved in 4–12% Bis-Tris gel (Invitrogen, Carlsbad, CA) for western blot detection of viral proteins using plasma from a SIV-infected rhesus macaque E544 as a primary antibody. As shown in Fig. 6A
Discussion In this study, using cultured macaque macrophages as an in vitro model, we demonstrated that non-integrated viral DNA can transcribe persistently in infected macrophages. In contrast to the transient presence of non-integrated viral DNA in T cells, the non-integrated SIV DNA was found to have a remarkable capacity to persist and remain transcriptionally active in macrophages. Non-integrated viral DNA and its transcripts persisted for 20 days, with minimal decay of the transcriptional activity. Additionally, some viral proteins were found to be synthesized and persisted in infected macrophages. These data suggested non-integrated viral DNA could support long-term, low level viral protein production in non-divided macrophages with the potential as a therapeutic vaccine. The nature of the transcribing, non-integrated HIV/SIV DNA in macrophages has not yet been determined. Non-integrated DNA has three different forms: linear, 1-LTR-circle, and 2-LTR-circle DNA (Pauza and Galindo, 1989). Previous studies showed that HIV 2-LTR-circles are rapidly lost in dividing cell populations, such as primary CD4+ T lymphocytes (Pauza et al., 1994). Recent work demonstrated that 2-LTR-circles persist out up to 21 days post-infection in macrophages, a non-dividing target of HIV-1 (Gillim-Ross, Cara, and Klotman, 2005a). 2-LTR-circles have been detected in the PBMCs of HIV-1 infected patients on suppressive therapy (Cara et al., 2002; Sharkey et al., 2000). They may also persist in non-dividing cells of PBMC such as the resting memory CD4+ T lymphocytes (Chun et al., 2000). Extra-chromosomal circular DNA in non-dividing cells such as macrophages could be a source of persistent viral protein expression. Also, the macrophage population utilized in our study served as a model of a primary non-dividing cell population, non-integrated HIV/SIV may persist in other non-dividing cell populations such as memory CD4+ T lymphocytes (Chun and Fauci, 1999; Chun et al., 1997). Persistent transcription ability of non-integrated SIV DNA in non-dividing cells may have unknown functions and be important for SIV pathogenesis. Previous research of D116N mutant HIV-1 in CD4+ T cells, demonstrated transient expression of both early and late messages by nonintegrated HIV DNA. However, only the early multiply spliced transcripts were measurably translated (Wu and Marsh, 2003a). The selective expression of early proteins from unintegrated HIV-1 templates has been hypothesized to result from low levels of Rev expression (Wu and Marsh, 2003a). During the late phase of infection, Rev promotes nuclear export and enables the cytoplasmic expression of single spliced and unspliced transcripts and therefore the translation of structural proteins. In contrast with these findings with HIV-1 integrase mutants, we observed persistent low level synthesis of both early and structural proteins from nonintegrated SIV DNA in macrophages. The transcription profile of the SIV D116N mutant was consistent with the hypothesis that low levels of Rev were responsible for the low level expression of structural proteins. In addition, low level expression of structural proteins of SIVsmD116N could be due to the difference in target cells used in the two studies (T cells versus macrophages) or to a difference in the amount of SIV Rev required for structural protein synthesis as compared to HIV. However, the HIV and SIV D116N mutants are similar in all other respects including the lack of detectable virus production. Our SIV mutant also expressed diminishing levels of the Vif transcript. The major cell types for infection, CD4 T cells and macrophages, are restrictive for HIV/SIV replication and require Vif for maintaining viral infectivity (Goncalves et al., 1996). Thus the Vif protein of HIV is required during late stages of viral production to counter the antiviral activity of APOBEC3G, a protein expressed notably in human T lymphocytes. When produced in the presence of APOBEC3G, vif-defective virus is non-infectious (Mangeat et al., 2003). An effective vaccine is urgently needed to stop the continuing spread of HIV worldwide. However, the development of an AIDS vaccine is proving to be an unprecedented challenge (Nabel, 2002). The lack of functional virus-specific effector T lymphocytes and neutralizing antibodies is a key immunogical feature of chronic HIV and SIV infections (Singh, Jeang, and Smith, 2005). The path to an HIV vaccine has been fraught with difficulties mainly because of the virulent nature of the virus and its ability to thwart the immune system over time (Letvin and Walker, 2003). Clearly an integrase mutant such as used in the present study did not express viral proteins efficiently as required for an immunogen and would have an inherent risk of reversion. However, the capacity of a non-integrating SIV to persistently generate viral proteins in macrophages implies that non-integrating lentiviral vectors could be engineered to more efficiently express proteins for use as a therapeutic vaccine, without the permanency of an integrated retrovirus or disruption of normal cellular genes. Materials and Methods Construction of Non-integrating mutant of SIVsmD116N clone The SIVsmE543-3 DNA sequence was changed from “GAT” to “AAT”, by substitution of “G” at site 4877 with “A” using the QuikChange site-directed mutagenesis kit (Stratagene, La Jalla, CA). Initially we derived a 2644 nt subclone of SIVsmE543 by PCR with Subclone-1 and Subclone-2 primers (Table 1) using the Top10 cloning kit (Invitrogen, Carlsbad, CA) and QuikChange PCR used to derive subSIVD116N according to the manufactures protocols. Mutagenic-1 and mutagenic-2 primers (Table 1) were designed according to Stratagene primer design software. SubSIVsmD116N and SIVsmE543 were digested by BstE II/BstB I, and the 2561bp fragment with the correct mutation was ligated into the 12Kb SIVsmE543 vector to construct the SIVsmD116N plasmid. The SIVsmD116N plasmid was sequenced to confirm that it contained only the desired mutation. Viruses, cells, and replication assay The SIVsmD116N and WT SIVsmE543-3 clones were transfected into 293T cells to generate cell free viruses using FuGENE transfection reagent (Roche, Indianapolis, IN) according to the manufacturer’s instructions. Cell free virus supernatants used for subsequent infections were treated with DNase I (Invitrogen, Carlsbad, CA) at 25°C for 10 min. to remove contaminating plasmid DNA. CEM×174 T cells, PBMC, and MDM were infected with cell free supernatant normalized for p27 antigen content from 293T cells transfected with SIVsmD116N or SIVsmE543 viruses (a multiplicity of infection 0.2). Cells were incubated with virus for 2–3 hours, then pelleted and resuspended in fresh culture medium. Virus replication was detected by 32P reverse transcriptase (RT) assay as previously reported (Sears, Repaske, and Khan, 1999). For experiment control, SIVsmD116N or SIVsmE543 viruses were heated on 56°C for 60 min to be inactivated and then were used to infect cells. Culturing of Monocyte-derived Macrophages (MDMs) To obtain MDMs, PBMCs were separated from whole blood by Percoll density centrifugation and were cultured in 48-well plates in RPMI 1640 medium (Life Technologies, Rockville, MD) containing 15% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, Utah), 10% human type AB serum (Sigma, St.Louis, MO) and 500 units/ml macrophage colony-stimulating factor (M-CSF, R&D systems, Minneapolis, MN) for five days. Cells were washed 3–5 times with pre-warmed RPMI 1640 medium to remove non-adherent cells. Adherent cells were maintained in fresh RPMI 1640 medium containing 15% heat-inactivated FBS, 5% human type AB serum and 200 units/ml M-CSF for two days, after which they were infected with viruses. DNA and RNA isolation and detection Total cellular DNA and RNA were purified using SV total RNA isolation kit (Promega, Madison, WI, USA), as recommended by the manufacturer. The primer sequences used to detect viral RNA and DNA are listed in Table 1. For the detection of full-length viral DNA by PCR, forward SIV/DNA-5 primer and anti-sense SIV/DNA-3 primer were used. PCR was carried out in 1 x Ambion PCR buffer, 125μM dNTP, 50 pmol each primer, 1U SuperTaq Plus (Ambion, Austin, TX) with 30 cycles of 94°C for 20s, 60°C for 30s, 68°C for 40s. Both the 1-long terminal repeat (LTR) circles and 2-LTR-circles, SIV/Circle-5′ primer and SIV/Circle-3′ primer were used for detection of circular viral DNA forms. For detection of viral RNA species, reverse transcription of cellular RNA was accomplished with random decamers as the first-strand primers. Following cDNA synthesis, PCR was performed using SIV/5′ primer and SIV/nef-tat-rev primer to amplify doubly spliced viral transcripts Nef, Tat and Rev. For relative quantification of RT-PCR, cellular β-actin transcripts were co-amplified using QuantumRNA β-actin Internal Standards (Ambion, Austin, TX), with a ratio of 3/7 for actin primer/competitor. For analysis of singly spliced viral transcripts such as the Env transcript, SIV/5′ primer and SIV/3′ env primer were used, whereas for the Vif transcript, SIV/5′ primer and SIV/3′ vif primer were used. For analysis of Gag-Pol transcript, SIV/5′ primer and SIV/3′ gag-pol primer were used. Assay for integration To detect SIV integration into the host genome, we used an Alu sequence-based PCR strategy to amplify the junction between the nearest Alu sequence and the SIV LTR. Nested PCR was used for Alu-PCR, with Alu 1-1 primer corresponding to human Alu sequence position 172–196, and Alu 1–2 primer located in the U3 region (bp230-207) of SIV LTR (Zhuge et al., 2001). Following the first round of Alu-PCR, a second round of PCR was carried out by using a 1:500 dilution of the first round PCR product as a template and the LTR specific primers Alu 2-1 and Alu 2-2 (Table 1). The amplification conditions for Alu-PCR were 35 cycles of 94°C for 20s, 65 ° C for 30s, 68° C for 40s. To ensure that the second round PCR products were derived from first round PCR product (integrated DNA) rather than non-integrated DNA carry-over, a 1:500 dilution of the original DNA samples were used as templates for second round PCR as a negative control. Immunodetection of viral protein Western blotting was performed for detecting viral protein expression. Samples were run on 4–12% Bis-Tris gel (Invitrogen, Carlsbad, CA) and transferred to 0.2um nitrocellulose membrane in a Novex Mini-Cell unit (Invitrogen, Carlsbad, CA) as suggested by manufacturer. For figure 1 Acknowledgments We thank Yuntao Wu for help in experimental design, Robert Goeken and Charles Brown for technical assistance, Russell Byrum for providing macaque blood samples, and Takeo Kuwata for beneficial discussion. This work was supported by the intramural program of NIAID, NIH. Footnotes Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Proc Natl Acad Sci U S A. 1992 Jul 15; 89(14):6580-4.
[Proc Natl Acad Sci U S A. 1992]Retrovirology. 2004 Jun 25; 1():13.
[Retrovirology. 2004]J Virol. 1990 May; 64(5):2421-5.
[J Virol. 1990]J Virol. 1995 Jan; 69(1):376-86.
[J Virol. 1995]J Virol. 2003 Oct; 77(19):10376-82.
[J Virol. 2003]J Virol. 1995 May; 69(5):2729-36.
[J Virol. 1995]J Virol. 1997 Feb; 71(2):1608-20.
[J Virol. 1997]J Virol. 2003 Jun; 77(11):6405-18.
[J Virol. 2003]J Virol. 2004 Jan; 78(1):275-84.
[J Virol. 2004]J Virol. 1995 May; 69(5):3216-9.
[J Virol. 1995]J Virol. 1995 Jan; 69(1):376-86.
[J Virol. 1995]Virology. 2001 Sep 1; 287(2):436-45.
[Virology. 2001]Science. 2001 Aug 24; 293(5534):1503-6.
[Science. 2001]Microbes Infect. 2003 Sep; 5(11):1023-7.
[Microbes Infect. 2003]J Virol. 1989 Sep; 63(9):3700-7.
[J Virol. 1989]Virology. 1994 Dec; 205(2):470-8.
[Virology. 1994]Viral Immunol. 2005; 18(1):190-6.
[Viral Immunol. 2005]Virology. 2002 Jan 5; 292(1):1-5.
[Virology. 2002]Nat Med. 2000 Jan; 6(1):76-81.
[Nat Med. 2000]J Virol. 2003 Oct; 77(19):10376-82.
[J Virol. 2003]J Virol. 1996 Dec; 70(12):8701-9.
[J Virol. 1996]Nature. 2003 Jul 3; 424(6944):99-103.
[Nature. 2003]Vaccine. 2002 May 6; 20(15):1945-7.
[Vaccine. 2002]Front Biosci. 2005 Sep 1; 10():2064-81.
[Front Biosci. 2005]Nat Med. 2003 Jul; 9(7):861-6.
[Nat Med. 2003]J Clin Microbiol. 1999 Jun; 37(6):1704-8.
[J Clin Microbiol. 1999]Virology. 2001 Sep 1; 287(2):436-45.
[Virology. 2001]